Abstract

Objective: To explore the clinical effect of applying the pre-excitation regimen in the treatment of patients with refractory relapsed acute non-lymphocytic leukemia (ANLL). Methods: This research work was carried out in our hospital (Shaanxi Provincial People’s Hospital) from September 2021 to September 2022. A total of 50 cases were selected for this study, and all were given a pre-excitation treatment plan, mainly low-dose cytarabine, aclarithromycin, etoposide, granulocyte colony-stimulating factor, and more were implemented. The clinical intervention effect was then analyzed. Results: Among the 50 patients in this study, the results showed that the treatment was very effective for 22 cases, accounting for 44.00%; effective for 14 cases, accounting for 28.00%; and ineffective for 14 cases, accounting for 28.00%. The total rate of effectiveness was 72.00%. The hematopoietic system adverse reactions of the patients were mainly bone marrow suppression. All 50 patients had different degrees of blood count decline, among which some patients’ neutrophils were less than 0.5×109 /L. The median time was 7 days. Among them, 25 patients had infection problems, the incidence rate was 50.00%, the patient’s platelet count PLT < 20 × 109/L, and the median time was 10 days. At the same time, among the 50 patients in this study, 34 (68.00%) patients had symptoms such as loss of appetite, nausea, vomiting, and fatigue, 17 (34.00%) patients showed hair loss, mildly elevated transaminases were observed in 8 (16.00%) patients, and 11 (22.00%) patients had muscle soreness. Conclusion: In the treatment of patients with refractory complex acute non-lymphocytic leukemia, the application of pre-excitation regimen has a significant effect, which can improve the adverse symptoms of patients, reduce the incidence of adverse reactions, and promote the recovery of patients.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call